Navigation Links
Gerresheimer Expands in the Global Pharmaceutical Plastic Business
Date:9/22/2009

he plant is deemed to be the biggest production center of its kind in Southern Europe and is a significant strategic base for Gerresheimer there as well as in the Central European region. Pharmaceutical bottles and multifunctional dosage and closure systems, for example for eye drops, contact lens care products, nose sprays as well as tablets, are being produced there.

With the help of significant acquisitions, targeted investments and organic growth Gerresheimer has accelerated its plastics business during the past five years and developed it into an internationally leading market force. All in all, the company now possesses 15 locations in Europe, America and Asia in this sector. Both segments of the plastics division are continuing to attain above average growth rates. Accounting for a third of group sales, plastics have already become the largest growth area within the Gerresheimer Group.

About Gerresheimer

Gerresheimer employs around 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totaled EUR1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

    Contact Press:
    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.co

    Contact Investor Relations:
    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121
    e-mail '/>"/>
SOURCE  Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 

Related medicine news :

1. Standard & Poors Confirms Rating for Gerresheimer
2. Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed
3. Gerresheimer Continues Expansion Course
4. Blackstone Sells Gerresheimer Stake
5. Standard & Poors Raises Gerresheimer Rating to BB+
6. Gerresheimer Starts the Year Successfully in 2008
7. Gerhard Schulze New Chairman of the Supervisory Board of Gerresheimer AG
8. Gerresheimer Finalises Purchase of Spanish Company EDP
9. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
10. Linnartz New Head of Investor Relations of Gerresheimer
11. Growth Trend for Gerresheimer Continues Unabated - Debt Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , QUINCY, Mass., Nov. 20 Fo...upermarket Company removed from sale Shedd,s Count...i Rice and Shedd,s Country Crock ® Side Dishe...lfite allergen. ,, The following code dates an...® Side Dishes DELUXE Cheddar Broccoli Rice 21...
(Date:11/20/2009)..., , ST. LOUIS, Nov. 20 /PRNewswire-FirstCa...announced that it will present at the Bank of Amer...ld December 2-3, 2009, at the Crowne Plaza Hotel T...resent Wednesday, December 2nd at 8:30 a.m. Easter... access a live, audio webcast of Centene,s present...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 /PRNewswire-FirstC...nnounced that it will broadcast Doctor Radio Re...rams , an in-depth special hosted by veteran journ...om.com/cgi-bin/prnh/20080819/NYTU044LOGO ) ,, ...Know About Mammograms will air November 21 live...
(Date:11/20/2009)...(Seattle, Washington) November 20, 2009Emergency m...s assess an estimated 350,000 cardiac arrests each...dden cardiac arrest survive. Better quality cardi...ital EMS providers may be associated with better p...tium (ROC) is the largest clinical research networ...
(Date:11/20/2009)...nadian study finds more severe cases than with sea...y News) -- Canadian researchers are reporting that...evere cases of H1N1 flu than seasonal flu. , "A...ctor for admission with pandemic H1N1 influenza, p...amples," wrote Dr. Upton Allen and fellow research...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...eveals patients at much greater risk for death , ...ent" heart attacks occur more often than previousl...premature death, according to a Duke University Me...don,t cause any pain and don,t leave behind tellta...
...ces absorption of rapamycin 3 to 4 times , ...t juice boosts the anti-cancer effects of the drug...ed 25 patients with advanced solid tumors, for whi...study, they also drank a glass (eight ounces) of g...
... Corporation (NYSE: SYK ) reported operating res...ws: , , First Quarter Highlights , , , , ...cy basis (2.0% decrease as reported) to $1,601 mil...sed 1.0% on a constant currency basis (5.3% decrea...
...vantages, limits of procedure, study suggests , ...-assisted surgery may be useful for removal of cer..., Their study included 36 patients with oral cavit...e margins (when no cancer cells are found at the e...
...ave a loved one take a look, study says , ... delivers a lifesaving message to older men about ...ma: If you can,t examine your own back, have a lov...it usually is thinner compared to a person finding...
... Medical Innovations, Inc. (NYSE: IMA ), a globa... their health at home through the merger of rapid ... that it will release its first quarter 2009 earni...ts and other corporate matters. During the confere...
Other Medicine News:Health News:'Silent' Heart Attacks More Common Than Thought 2Health News:Grapefruit Juice Boosts Anti-Cancer Drug's Effects 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 3Health News:Stryker Operating Results for Quarter Ended March 31, 2009 4Health News:Stryker Operating Results for Quarter Ended March 31, 2009 5Health News:Stryker Operating Results for Quarter Ended March 31, 2009 6Health News:Stryker Operating Results for Quarter Ended March 31, 2009 7Health News:Stryker Operating Results for Quarter Ended March 31, 2009 8Health News:Robotic Surgery Practical for Some Head, Neck Tumors 2Health News:Older Men Need to Take Closer Look for Melanomas 2Health News:Older Men Need to Take Closer Look for Melanomas 3Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results 2
(Date:11/20/2009)...Nov. 20 Escalon Medical ...for its fiscal first quarter ended September 30, 2... product revenue decreased approximately $234,000,...iod ended September 30, 2009 as compared to the sa...the decreased net revenue of $8,434,000 compared w...
(Date:11/20/2009)...l., Nov. 20 /PRNewswire-FirstCall/ -- Landauer,...r the fiscal fourth quarter and full year of 2009 ... company will host a conference call for investors...n Time. Investors may access the live call by dial...ada), or 480-629-9835 (international callers), or ...
(Date:11/20/2009)...K, Nov. 20 Reportlinker.com announ... in its catalogue. ,, Pipettes & Pipettors....reportlinker.com/p0164373/Pipettes--Pipettors---A...ire&utm_medium=pr&utm_campaign=prnewswire ...ntegral part of any research laboratory. Large-sca...
Breaking Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 1Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 2Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 3Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 4Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 1Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 2Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 3Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 1Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 2Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 3Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 5
...e Phase III ZODIAC study in advanced non-small cel...rug vandetanib, were presented today at the Americ...Orlando. Results show that the study met its prima...ndetanib to docetaxel resulted in a statistically ...al (PFS), the length of time a patient lives witho...
...hat Induction Chemotherapy prior to ChemoRadiother...ure in comparison to standard ChemoRadiotherapy al...ck Cancer Cooperative Group (TTCC) announced today...to standard ChemoRadiotherapy (CRT), a treatment p... upfront CRT alone, significantly prolonged Time-t...
Other Medicine Technology:Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 2Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 3Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 4Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 5Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 2Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 3
...A nonabsorbable knitted product for use in hernior... flexible and compliant material that affords exce...ty, along with maximal porosity for necessary tiss...nstructed from polyethylene terephthalate, the sam...
...The 800 Series KTP/YAG Surgical Laser System is de..., dual-wavelength system designed for urology, gyn...l surgery, neurosurgery, pulmonary surgery and gas...lly cuts, vaporizes and coagulates tissue with min...
...The Gemini is the newest addition to Laserscopes f... distinct wavelengths to choose from, 1064nm Nd:YA...ding non-invasive aesthetic laser market by pushin...ness while maintaining the safety and reliability ...
...The Venus-i Laser System is a new, portable, light...pplications in dermatology, cosmetic and plastic s... ideal laser for skin resurfacing, it is the small...s on the market. It provides an ideal treatment fo...
Medicine Products: